Volume | 26,304 |
|
|||||
News | - | ||||||
Day High | 1.1523 | Low High |
|||||
Day Low | 1.0297 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
NanoViricides Inc | NNVC | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.11 | 1.0297 | 1.1523 | 1.11 | 1.15 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
141 | 26,304 | $ 1.09 | $ 28,774 | - | 1.00 - 2.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
20:00:00 | 100 | $ 1.11 | USD |
NanoViricides Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
13.07M | 11.78M | - | 0 | -8.59M | -0.73 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
NanoViricides News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NNVC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.15 | 1.28 | 1.0297 | 1.13 | 15,151 | -0.04 | -3.48% |
1 Month | 1.12 | 1.50 | 1.0297 | 1.28 | 37,232 | -0.01 | -0.89% |
3 Months | 1.12 | 1.50 | 1.0297 | 1.23 | 30,144 | -0.01 | -0.89% |
6 Months | 1.16 | 1.50 | 1.00 | 1.18 | 39,793 | -0.05 | -4.31% |
1 Year | 1.27 | 2.00 | 1.00 | 1.34 | 52,801 | -0.16 | -12.60% |
3 Years | 4.20 | 7.86 | 1.00 | 4.81 | 338,164 | -3.09 | -73.57% |
5 Years | 0.266 | 19.80 | 0.16045 | 7.12 | 688,761 | 0.844 | 317.29% |
NanoViricides Description
Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy. |